News
Vesigen Highlights New Data on Non-Viral Delivery Platform at the Exosome Based Therapeutic Development Summit
CAMBRIDGE, Mass., September 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Highlights Therapeutic Platform for Non-Viral Delivery of Gene Editors and RNA at ASGCT 2023
CAMBRIDGE, Mass., May 22, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
CAMBRIDGE, Mass., May 2, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
CAMBRIDGE, Mass., March 14, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing targeted therapies by engineering a ...
Vesigen Therapeutics, Inc. Announces Expansion of Scientific Advisory Board
CAMBRIDGE, Mass., February 7, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Vesigen Therapeutics Names Rakhshita Dhar to Board of Directors
CAMBRIDGE, Mass., January 30, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Stay Connected
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
